KMC Speciality Hospitals FY26: +118% PAT, Sales ₹305.77 cr

Key update: board meet on 14 August 2026

KMC Speciality Hospitals (India) Ltd (NSE: KMCSHIL; BSE: KMCSHIL) has scheduled a board meeting for Friday, 14 August 2026. The company said the meeting will consider and approve unaudited financial results for the quarter ended 30 June 2026. The date matters because it sets the next near-term disclosure point for investors after the company’s audited FY26 outcome.

The update comes alongside a set of financial numbers for FY26 and Q4 FY26 (March 2026 quarter) that show a sharp year-on-year improvement in profit. Separately, the stock was shown at multiple price points in the provided data, including ₹124.30 (+0.36%) and a “current share price” reference of ₹123.6, while another line showed trading at ₹116.55.

FY26 results: revenue growth and profit expansion

In the stated board meeting outcome (dated 29 May 2026 in the provided text), KMC Speciality Hospitals reported standalone revenue of ₹305.77 crore for FY26. This was described as a 32.03% year-on-year increase.

Net profit for FY26 was reported at ₹46.73 crore, a 118.1% year-on-year rise. The same dataset also lists FY26 EPS at ₹2.87. Another FY26 snapshot table showed income of ₹311 crore and net profit of ₹46.73 crore, indicating the narrative and tables are broadly consistent on profitability while income is shown with slight rounding differences.

Q4 FY26: profit up 223.67% YoY, modest QoQ lift

For Q4 FY26, the company disclosed revenue from operations of ₹82.25 crore and net profit of ₹14.63 crore. The text also states that Q4 FY26 net profit jumped 223.67% versus the same period last year.

On a sequential basis, Q4 FY26 net profit was up 6.55% (also stated as 6.57% in a separate line) compared with the preceding quarter. Total income for Q4 FY26 was reported at ₹84.1588 crore, compared with ₹83.1858 crore in Q3 FY26, implying a quarter-on-quarter increase of 1.17%.

Per-share profitability for Q4 FY26 was reported at ₹0.90 (basic and diluted), compared with ₹0.84 in Q3 FY26 and ₹0.27 in Q4 FY25.

Q3 FY26 reference: growth versus Q3 FY25

The data also provides a comparison for Q3 FY26 versus Q3 FY25. For Q3 FY26, revenue was ₹82.0603 crore versus ₹61.3641 crore in Q3 FY25, a change of 34%. Profit before tax (PBT) was ₹18.4752 crore versus ₹10.0482 crore (up 84%). Profit after tax (PAT) was ₹13.7278 crore versus ₹7.5138 crore (up 83%). EPS for Q3 FY26 was ₹0.84.

This Q3 reference helps explain the strong year-on-year profit trajectory that carried into Q4, culminating in the FY26 net profit figure.

Quarterly trajectory: sales rising into FY26

Quarterly sales figures provided across multiple quarters show a steady upward move into FY26. A separate quarterly table lists net sales rising from ₹60.94 crore (Mar 2025) to ₹66.55 crore (Jun 2025), ₹74.9 crore (Sep 2025), ₹82.06 crore (Dec 2025), and ₹82.25 crore (Mar 2026).

The same table shows total expenditure of ₹56.38 crore in Mar 2026, operating profit of ₹25.87 crore, other income of ₹1.91 crore, and interest cost of ₹2.03 crore for the quarter.

Annual financials snapshot: FY15 to FY26 trend

Annual financials in the provided dataset show revenue increasing from ₹37 crore (FY15) to ₹306 crore (FY26). Expenses increased from ₹31 crore to ₹218 crore over the same period, while EBITDA rose from ₹6 crore to ₹88 crore.

Operating profit margin is shown improving to 29% in FY26 (from 25% in FY25 and 27% in FY24). Net profit is listed at ₹47 crore in FY26 in one annual table, while a more detailed FY26 outcome table reports net profit at ₹46.73 crore.

Shareholding and trading references

The shareholding pattern note states promoter holding remained unchanged at 75.00% in the June 2026 quarter. The same section lists other holders with small percentages, but without additional context on categories beyond the displayed names.

On price references, the data includes ₹124.30 (+0.45, +0.36%) and a separate line stating the “current share price” as ₹123.6. Another table cites a share price of ₹119.3 on 15 June 2026 with -₹0.65 (-0.54%) shown, and another line shows the stock trading at ₹116.55.

Summary table: latest disclosed financial metrics (₹ crore)

Market impact: what the numbers signal (without forecasts)

The FY26 outcome combines mid-30% revenue growth (as stated) with a much faster rise in net profit. In practical terms, the company converted higher quarterly sales into stronger bottom-line performance through FY26, as reflected in the Q4 PAT of ₹14.63 crore and FY26 PAT of ₹46.73 crore.

For investors tracking near-term catalysts, the next event is the 14 August 2026 board meeting to approve unaudited results for the quarter ended 30 June 2026. The stock price references in the data indicate active trading around the ₹116.55 to ₹124.30 range in June 2026 snapshots, but they are timestamped inconsistently and should be read as point-in-time quotes.

Conclusion

KMC Speciality Hospitals’ disclosed FY26 numbers show revenue of ₹305.77 crore and net profit of ₹46.73 crore, with Q4 FY26 profit at ₹14.63 crore and EPS at ₹0.90. The company’s next scheduled disclosure is the board meeting on 14 August 2026 to consider and approve unaudited financial results for the quarter ended 30 June 2026.